PMM1 Human Pre-designed siRNA Set A contains three designed siRNAs for PMM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PMM2 Human Pre-designed siRNA Set A contains three designed siRNAs for PMM2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PMMB276 is a potent inhibitor of β-tubulin isotype III (Tubb3) polymerization and induced apoptosis. PMMB276 plays an important role in cancer research[1].

PMP2 Human Pre-designed siRNA Set A contains three designed siRNAs for PMP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PMP22 Human Pre-designed siRNA Set A contains three designed siRNAs for PMP22 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PMPCA Human Pre-designed siRNA Set A contains three designed siRNAs for PMPCA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PMPCB Human Pre-designed siRNA Set A contains three designed siRNAs for PMPCB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PMS1 Human Pre-designed siRNA Set A contains three designed siRNAs for PMS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PMS2 Human Pre-designed siRNA Set A contains three designed siRNAs for PMS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PMVK Human Pre-designed siRNA Set A contains three designed siRNAs for PMVK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNB-001 is an orally active CCK2 selective ligand and antagonist. PNB-001 has anti-inflammatory and analgesic activities[1].

PNB-001 is an orally active CCK2 selective ligand and antagonist. PNB-001 has anti-inflammatory and analgesic activities[1].

PNCK Human Pre-designed siRNA Set A contains three designed siRNAs for PNCK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pneumolysin-IN-1 (compound PB-3) is a targeted small molecule inhibitor of Pneumolysin (PLY) (IC50=3.1 µM). Pneumolysin-IN-1 is a pore blocking agent and an anti-virulence factor. Pneumolysin-IN-1 can be used to study the infection caused by Streptococcus pneumoniae[1].

PNI 132, an ionizable lipid derived from the patent WO2020252589A, is useful in the formulation of lipid nanoparticles.

PNISR Human Pre-designed siRNA Set A contains three designed siRNAs for PNISR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNKD Human Pre-designed siRNA Set A contains three designed siRNAs for PNKD gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNKP Human Pre-designed siRNA Set A contains three designed siRNAs for PNKP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNLDC1 Human Pre-designed siRNA Set A contains three designed siRNAs for PNLDC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNLIP Human Pre-designed siRNA Set A contains three designed siRNAs for PNLIP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNLIPRP1 Human Pre-designed siRNA Set A contains three designed siRNAs for PNLIPRP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNLIPRP2 Human Pre-designed siRNA Set A contains three designed siRNAs for PNLIPRP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNMA2 Human Pre-designed siRNA Set A contains three designed siRNAs for PNMA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNMA3 Human Pre-designed siRNA Set A contains three designed siRNAs for PNMA3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNMT Human Pre-designed siRNA Set A contains three designed siRNAs for PNMT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNN Human Pre-designed siRNA Set A contains three designed siRNAs for PNN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNO1 Human Pre-designed siRNA Set A contains three designed siRNAs for PNO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNOC Human Pre-designed siRNA Set A contains three designed siRNAs for PNOC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNP Human Pre-designed siRNA Set A contains three designed siRNAs for PNP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNPLA1 Human Pre-designed siRNA Set A contains three designed siRNAs for PNPLA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNPLA2 Human Pre-designed siRNA Set A contains three designed siRNAs for PNPLA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pnpla2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pnpla2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNPLA2 Rat Pre-designed siRNA Set A contains three designed siRNAs for PNPLA2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNPLA3 Human Pre-designed siRNA Set A contains three designed siRNAs for PNPLA3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNPLA4 Human Pre-designed siRNA Set A contains three designed siRNAs for PNPLA4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNPLA5 Human Pre-designed siRNA Set A contains three designed siRNAs for PNPLA5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNPLA6 Human Pre-designed siRNA Set A contains three designed siRNAs for PNPLA6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNPLA7 Human Pre-designed siRNA Set A contains three designed siRNAs for PNPLA7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNPLA8 Human Pre-designed siRNA Set A contains three designed siRNAs for PNPLA8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNPO Human Pre-designed siRNA Set A contains three designed siRNAs for PNPO gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

pNPS-DHA (Compound 19) is an orally active DHA-ethanolamide (DHEA) derivative that has antiallergic activity. pNPS-DHA inhibits IgE-dependent passive cutaneous anaphylaxis (PCA) reaction in mice. pNPS-DHA has anti-degranulating activity in RBL-2H3 mast cells with an IC50 of 15 μM[1].

PNPT1 Human Pre-designed siRNA Set A contains three designed siRNAs for PNPT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNRC1 Human Pre-designed siRNA Set A contains three designed siRNAs for PNRC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNRC2 Human Pre-designed siRNA Set A contains three designed siRNAs for PNRC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PNU-100766-d8 is deuterated labeled Linezolid (HY-10394). Linezolid (PNU-100766) is the first member of the class of oxazolidinone synthetic antibiotic. Linezolid acts by inhibiting the initiation of bacterial protein synthesis. Linezolid is used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics[1][2][3].

PNU-22394 hydrochloride is an agonist for 5-HT, with Ki of 6.1 and 10 nM, for 5-HT2C and 5-HT2A, respectively[1].